EVR RX v.s. HL NYC RX
Title. Which offer would you pick if you have both? Both are for SA 2024 and in the NYC office. Thank you!
Trending Content
Career Resources
WSO Free Modeling Series - Now Open Through
May 31, 2024
9 Free Financial Modeling Lessons
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
+Bonus: Get 27 financial modeling templates in swipe file
+Bonus: Get 27 financial modeling templates in swipe file
They're both elite groups - pick based on who you vibed with more.
If all else is strictly indistinguishable then I would pick EVR - way better firm recognition (outside of those who know Rx) and the group is killing it right now.
Evercore: stronger name outside of finance, higher pay
Houlihan: stronger name in RX, better hours
First criteria is fit. Both are excellent names and you can't go wrong with either, so do the one where you can see yourself getting along with others in the bullpen.
If you're completely indifferent fit-wise, would choose EVR RX. Viewed as a better analyst program and will work with smarter kids.
If your a hardo for RX, go HL RX. Historically the #1 player in the space. Sure evercore as a firm overall is more prestigious, but HL RX is still top dog.
I would argue EVR is better considering they do debtor work. HL Rx is just a volume creditor shop. They have like 200 rx employees while everyone else has max 40.
Don’t know why this forum has a hard-on for HL Rx. The experience you get there would be worse than any EB Rx, unless you’re staffed on their premier deals.
HL has a stronger global presence than other EB RX groups, hence the bigger group size. If we are talking about HL RX in the US, the split between debtor and creditor work is roughly 50-50. HL RX is also known for offering one of the best group culture and analyst experience on the street. You clearly have no idea what you are talking about, prospect.
You clearly work at HL. You can even see in Rx league tables they have 4x the group size yet in Q4 2022 they had 50% of the dollar volume advised than everyone else lmao.
HL does nothing special they are once again a volume shop, they are a solid shop but definitely below in terms of EB experience. Once again if you aren’t the top analyst you are going to be staffed on some BS creditor work of a company with a $25m capital structure. Evercore/Lazard are above HL Rx.
If you don't understand this, you don't go to a top target or are some random person.
8 SB in 18 minutes tf? Imagine making fake accounts to tip the scale in a dumb pissing contest.
Inaccurate. I personally know a Penn kid (JWS, so I’d argue they’re pretty top tier) that is returning + another JWS who is incoming SA.
Did you ask either of the teams about their on-cycle exits this year? I found both EVR and Laz higher ups happy to discuss and proud
Not sure about other offices but HL NY has had recent (last 2-3 years) exits to SPC, Oaktree, APO, BX, KKR, Centerbridge, with multiple analysts heading to several of the listed funds. From an exits perspective they're right up there with EVR and probably outdo Lazard, although they're definitely a step below PJT, which has had a consistent pipeline to APO PE.
League table argument is moot given a majority of the mandates these shops land are out-of-court, but HL does seem to be losing larger mandates to PJT and EVR. I'd venture to guess that analyst experience in NY is closer to PJT/EVR/LAZ/MOE, but probably not comparable for HL analysts in the satellite office.
Can confirm that HL RX has been killing it in terms of exits. I’d say they also have a pretty strong Apollo pipeline, both PE and HVF.
I love how where Wharton kids would go is like a real criteria to evaluate how prestigious an offer is